Award Year / Program / Phase:
2004 / STTR / Phase II
Agency:
HHS
Research Institution:
OREGON HEALTH & SCIENCE UNIVERSITY
Award Amount:
$720,140.00
RI Contact:
N/A
Abstract:
DESCRIPTION (provided by applicant): The broad, long-term objective of this project is to develop a new class of drugs for treatment of multiple sclerosis (MS). The lead compound in the current proposal is VG1000, a minimal recombinant TCR ligand (RTL) containing MHC class II (1(1 domains of…
More
Award Year / Program / Phase:
2005 / STTR / Phase II
Agency:
HHS
Research Institution:
OREGON HEALTH SCIENCES UNIVERSITY
Award Amount:
$751,716.00
RI Contact:
N/A
Abstract:
DESCRIPTION (provided by applicant): This is an STTR Phase II proposal to develop the application of a novel neuroprotectant in the treatment of stroke. As in our previous Phase I STTR, this Phase II STTR unites the Stenzel-Poore laboratory and Virogenomics, Inc., a Portland-based genomics and drug…
More
Award Year / Program / Phase:
2005 / STTR / Phase I
Agency:
HHS
Research Institution:
OREGON HEALTH & SCIENCE UNIVESITY
Principal Investigator:
Jianya Huan
Award Amount:
$100,548.00
RI Contact:
N/A
Abstract:
DESCRIPTION (provided by applicant): The specific goal of this Phase I STTR is to design, manufacture, characterize and evaluate a set of therapeutic agents that can control the pathogenic CD4+ T cells that mediate an inflammatory autoimmune disease, rheumatoid arthritis (RA). The approach presented…
More
Award Year / Program / Phase:
2007 / STTR / Phase I
Agency:
HHS
Research Institution:
OREGON HEALTH AND SCIENCE UNIVERSITY
Award Amount:
$588,104.00
RI Contact:
N/A
Abstract:
DESCRIPTION (provided by applicant): Tularemia is the severe and sometimes fatal disease caused by infection with Francisella tularensis. These bacteria are some of the most virulent pathogens known, requiring inoculation or inhalation with as few as 10 or
ganisms to cause disease. Infections can be…
More
Award Year / Program / Phase:
2008 / STTR / Phase I
Agency:
HHS
Research Institution:
N/A
Principal Investigator:
Award Amount:
$123,759.00
RI Contact:
N/A
Abstract:
DESCRIPTION (provided by applicant): The potential of treatment for stroke may be accomplished via acute intervention at the time of the acute stroke or by providing prophylactic neuroprotection to at risk populations. The at risk group includes: 1) co
ronary artery bypass surgery patients (who…
More
Award Year / Program / Phase:
2008 / STTR / Phase I
Agency:
HHS
Research Institution:
N/A
Principal Investigator:
Award Amount:
$123,614.00
RI Contact:
N/A
Abstract:
DESCRIPTION (provided by applicant): Immunotherapy as a treatment for cancer has been intensely investigated, but few studies have resulted in meaningful clinical responses. Many fundamental principals of tumor immunology have been clarified in recent year
s with the recognition and description of…
More
Award Year / Program / Phase:
2009 / STTR / Phase I
Agency:
HHS
Research Institution:
EMANUEL HOSPITAL AND HEALTH CENTER
Award Amount:
$118,342.00
RI Contact:
N/A
Abstract:
DESCRIPTION (provided by applicant): Stroke is the third leading cause of death and a leading cause of serious, long-term disability in the United States. Although in recent years enormous progress has been made towards defining the cellular and molecular
responses of the brain to ischemia, our…
More
Award Year / Program / Phase:
2010 / STTR / Phase I
Agency:
HHS
Research Institution:
Oregon Health And Science University
Award Amount:
$173,244.00
RI Contact:
Abstract:
DESCRIPTION (provided by applicant): Methamphetamine (MA) dependence is associated with neuropsychiatric side effects that make the addiction extremely challenging to treat. Patients seeking treatment experience ongoing impairments in cognition, mood, andmotivation. Currently, there are no…
More
Award Year / Program / Phase:
2012 / STTR / Phase II
Agency:
HHS
Research Institution:
OREGON HEALTH AND SCIENCE UNIVERSITY
Award Amount:
$1,350,283.00
RI Contact:
Abstract:
DESCRIPTION (provided by applicant): This application is a Phase II STTR to further the study of a novel therapeutic intervention for ischemic stroke. Phase I investigated the mechanism of protection against ischemic stroke provided by the novel designertherapy, recombinant T cell receptor ligand…
More